Compare VTRS & CF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTRS | CF |
|---|---|---|
| Founded | 1961 | 1946 |
| Country | United States | United States |
| Employees | 30000 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2B | 20.0B |
| IPO Year | 2019 | 2005 |
| Metric | VTRS | CF |
|---|---|---|
| Price | $13.15 | $133.62 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 15 |
| Target Price | $13.50 | ★ $108.36 |
| AVG Volume (30 Days) | ★ 8.0M | 5.4M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.58% | 1.53% |
| EPS Growth | N/A | ★ 33.09 |
| EPS | N/A | ★ 8.97 |
| Revenue | ★ $14,299,900,000.00 | $7,084,000,000.00 |
| Revenue This Year | $4.45 | $0.78 |
| Revenue Next Year | $1.79 | N/A |
| P/E Ratio | ★ N/A | $14.58 |
| Revenue Growth | N/A | ★ 19.34 |
| 52 Week Low | $6.85 | $67.49 |
| 52 Week High | $16.47 | $141.96 |
| Indicator | VTRS | CF |
|---|---|---|
| Relative Strength Index (RSI) | 40.44 | 62.91 |
| Support Level | $12.90 | $78.78 |
| Resistance Level | $13.49 | $139.70 |
| Average True Range (ATR) | 0.35 | 6.15 |
| MACD | 0.02 | -0.72 |
| Stochastic Oscillator | 34.16 | 68.36 |
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
CF Industries is a leading producer and distributor of nitrogen, which is primarily used in fertilizers. The company operates nitrogen manufacturing plants primarily in North America. CF also produces nitrogen in the United Kingdom and holds a joint venture interest in a nitrogen production facility in Trinidad and Tobago. CF makes nitrogen primarily using low-cost US natural gas as its feedstock, making the company one of the lowest-cost nitrogen producers globally. It is also investing in carbon-free blue and green ammonia, which can be used as an alternative fuel to hydrogen or as a means to transport hydrogen.